Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomised Controlled Trial to Evaluate Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille Calmette-Guerin (BCG) Vaccination in Infants of HIV Infected Mothers

NCT01650389 is registered in ClinicalTrials.gov with Mark Hatherill as lead sponsor.

NCT NCT01650389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01650389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomised Controlled Trial to Evaluate Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille Calmette-Guerin (BCG) Vaccination in Infants of HIV Infected Mothers
Lead sponsor
Mark Hatherill
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
May 31, 2015
Enrollment
248 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, tuberculosis